Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Sacubitril/Valsartan on sympathetic activity in heart failure
2017-000394-36Phase 4Terminated
- Sponsor
- Hannover Medical School
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Central sympathetic nerve traffic. Started Aug 2017; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2017-000394-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000394-36.